

# Comparable genomic copy number aberrations differ across astrocytoma malignancy grades

---

Pećina-Šlaus, Nives; Kafka, Anja; Gotovac Jerčić, Kristina; Logara, Monika; Bukovac, Anja; Bakarić, Robert; Borovečki, Fran

Source / Izvornik: **International Journal of Molecular Sciences**, 2019, 20, 1251 - 1251

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3390/ijms20051251>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:647655>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-07-16**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)





Article

# Comparable Genomic Copy Number Aberrations Differ across Astrocytoma Malignancy Grades

Nives Pećina-Šlaus <sup>1,2,\*</sup> , Anja Kafka <sup>1,2</sup>, Kristina Gotovac Jerčić <sup>3</sup>, Monika Logara <sup>4</sup>,  
Anja Bukovac <sup>1,2</sup>, Robert Bakarić <sup>5</sup> and Fran Borovečki <sup>3,6</sup>

<sup>1</sup> Laboratory of Neurooncology, Croatian Institute for Brain Research, School of Medicine University of Zagreb, Šalata 12, 10000 Zagreb, Croatia; anja.kafka@mef.hr (A.K.); anja.bukovac@mef.hr (A.B.)

<sup>2</sup> Department of Biology, School of Medicine, University of Zagreb, Šalata 3, 10000 Zagreb, Croatia

<sup>3</sup> Department for Functional Genomics, Center for Translational and Clinical Research, University of Zagreb, School of Medicine and University Hospital Center Zagreb, Šalata 2, 10000 Zagreb, Croatia; kristina.gotovac@mef.hr (K.G.J.); fbor@mef.hr (F.B.)

<sup>4</sup> Genom Ltd., Ilica 190, 10000 Zagreb, Croatia; monika.logara@gmail.com

<sup>5</sup> Exaltum ultra Ltd.; Vrbik 13, 10000 Zagreb, Croatia; rbakaric@exaltum.eu

<sup>6</sup> Department of Neurology, University Hospital Center Zagreb, Kišpatičeva 12, 10000 Zagreb, Croatia

\* Correspondence: nina@mef.hr; Tel.: +385-1-46-21-140; Fax: +385-1-45-90-199 or +385-1-49-20-050

Received: 13 February 2019; Accepted: 6 March 2019; Published: 12 March 2019



**Abstract:** A collection of intracranial astrocytomas of different malignancy grades was analyzed for copy number aberrations (CNA) in order to identify regions that are driving cancer pathogenesis. Astrocytomas were analyzed by Array Comparative Genomic Hybridization (aCGH) and bioinformatics utilizing a Bioconductor package, Genomic Identification of Significant Targets in Cancer (GISTIC) 2.0.23 and DAVID software. Altogether, 1438 CNA were found of which losses prevailed. On our total sample, significant deletions affected 14 chromosomal regions, out of which deletions at 17p13.2, 9p21.3, 13q12.11, 22q12.3 remained significant even at 0.05 *q*-value. When divided into malignancy groups, the regions identified as significantly deleted in high grades were: 9p21.3; 17p13.2; 10q24.2; 14q21.3; 1p36.11 and 13q12.11, while amplified were: 3q28; 12q13.3 and 21q22.3. Low grades comprised significant deletions at 3p14.3; 11p15.4; 15q15.1; 16q22.1; 20q11.22 and 22q12.3 indicating their involvement in early stages of tumorigenesis. Significantly enriched pathways were: PI3K-Akt, Cytokine-cytokine receptor, the nucleotide-binding oligomerization domain (NOD)-like receptor, Jak-STAT, retinoic acid-inducible gene (RIG)-I-like receptor and Toll-like receptor pathways. HPV and herpes simplex infection and inflammation pathways were also represented. The present study brings new data to astrocytoma research amplifying the wide spectrum of changes that could help us identify the regions critical for tumorigenesis.

**Keywords:** astrocytoma; aCGH; comparative genomic hybridization; copy number aberrations; GISTIC2.0.23

## 1. Introduction

Despite the advances in astrocytoma genetics and molecular characterization, many questions about the biology of these most common primary central nervous system tumors remain unanswered. The heterogeneity of their histological features is accompanied with marked genetic and genomic heterogeneity [1,2]. However, distinct genomic patterns are emerging, indicating the involvement of prominent signaling pathways, namely RTK/RAS/PI-3K, p53 and RB signaling [3–7]. Based on new discoveries on patterns of somatic mutations and DNA copy number variations involved in glioblastoma etiology, four molecular signatures were proposed that classify glioblastoma into proneural, neural, classical and mesenchymal [4,8].

World Health Organization (WHO) classifies astrocytomas into four grades [9,10] that denote their malignancy levels. Grades differ in tumor histology, growth potential, and tendency for progression, age distribution, behavior and prognosis. Astrocytomas grade I (pilocytic) typically shows that benign clinical behavior and malignant progression is extraordinarily rare, describing it as a benign tumor. Astrocytomas grades II and III (diffuse and anaplastic) can progress and evolve to grade IV tumors (glioblastoma). Primary glioblastomas arise de novo without cognition of precursory lesions of lower grades. The highly invasive nature of glioblastoma makes it a deadly malignant tumor that is still untreatable [11].

It has been shown by several investigations that genomic copy number changes play important roles in glioblastoma [12–17]. The objective of our present study was to discover genetic regions at high resolution that are altered in astrocytomas of different malignancy grades in order to identify candidate regions and genes that are appearing constantly across malignancy grades but also those that are specific for the progression of glial tumors.

Molecular mechanisms and genes involved in the formation and progression of astrocytomas are far from being fully understood. One of the unanswered questions is the progression of secondary glioblastoma from tumors of lower grades. The present study in which the grades of astrocytoma were compared with their genetic alterations aims to elucidate the events responsible for glioblastoma to acquire its marked malignancy. Thus, we performed a genome-wide survey of gene copy number changes using array comparative genomic hybridization (aCGH), the method that has been widely used in genetic profiling of different types of cancer [18,19].

Array CGH is a promising technology for studying copy number aberration (CNA) at higher resolutions. The technique compares genomic DNAs isolated from patients to reference samples that are differentially labeled with red and green fluorescent dyes and hybridized to known mapped segments of human genomic oligonucleotide probes. The latest arrays now have over a million in situ synthesized oligonucleotides attached to a slide. The importance of cancer-related CNA analysis using aCGH lies in the possibility to detect changes undergone relevant to tumorigenesis, i.e., silencing of tumor suppressor genes and boosting of oncogenes. There are several major advantages to aCGH including the ability to detect copy number changes at very high resolution, ease of implementation and the ability to analyze archival specimen. The resolving power of arrays progressively increased through the introduction of higher probe densities and through the use of synthetic oligonucleotides. This technology, however, comes with certain limitations, different platforms may yield different results, the lack of standardized bioinformatic algorithms and heterogeneous nature of cancer further complicates interpretation of obtained results. The limitations are overcome especially by the use of novel algorithms such as GISTIC (Genomic Identification of Significant Targets in Cancer).

aCGH is a reliable and sensitive technique for detecting gene CNA across the entire genome. Oligonucleotide microarrays provide high resolution and diagnostic yield of detection of copy number changes comprised in the tumor genome [20,21]. We were interested in characterizing unbalanced genomic changes gains/duplications and losses/deletions in our astrocytoma patients and offer potential candidate genes characteristic for malignancy grade as well as those recurring in several or all grades. Hence, we investigated the genomes of 14 intracranial astrocytic brain tumors of different WHO grades for changes in DNA copy number using high-resolution CGH arrays that contained 180,000 probes with the possibility to screen the genome with an average resolution of 10–50 kb. We further aimed to systematically analyze the information on CNA by a bioinformatics approach utilizing rCGH (Bioconductor package) and GISTIC 2.0.23. in order to comprehend which findings are relevant for astrocytoma biology.

## 2. Results

### 2.1. CNA in Our Total Astrocytoma Sample

We analyzed 14 astrocytoma samples which included two astrocytomas grade I, two astrocytomas grade II, one astrocytoma grade III and nine glioblastomas (grade IV) (Table 1). Autologous blood samples were also obtained and analyzed for two patients (one for grade I and the other for IV). The sample size was determined based on tumor incidence and on similarity to other studies of similar size in the investigated field. The frequencies of occurrence are rather different. Grade I (pylocytic) astrocytoma accounts for 2% of all brain tumors and 5.4% of all gliomas. Grade II (diffuse) astrocytomas account for approximately 11% of all astrocytic brain tumors. Grade III (anaplastic, malignant) astrocytoma accounts for 4% of all brain tumors while glioblastoma astrocytoma (grade IV) accounts for 45–50% of all primary malignant brain tumors. The aCGH profiles demonstrated many differences in astrocytoma DNA when compared to normal control on the array. The multitude of changes that we observed in astrocytoma cells is indicative of the accumulation of deletions and amplifications characteristic of tumor cells. Astrocytoma patients showed gains and losses on many chromosomal regions. There were also a substantial number of amplifications and deletions but lower than the frequencies of the first two types of aberrations. Altogether, our aCGH results showed 1438 CNA found across astrocytomas of different malignancy grades, including 21 amplifications, 397 gains, 929 losses and 91 deletions. Losses dominated over gains and deletions over amplifications.

**Table 1.** Clinical and epidemiological data for collected astrocytoma samples.

| Astrocyto-ma Samples | Grades | Localization           | Age at Diagnosis | Sex | Molecular Diagnosis |
|----------------------|--------|------------------------|------------------|-----|---------------------|
| 1 *                  | I      | Frontoparietal R       | 42               | M   | ND                  |
| 2                    | I      | Occipital R            | 19               | F   | ND                  |
| 3                    | II     | Temporal L             | 32               | M   | IDH1MUT; ATRXWT     |
| 4                    | II     | InsularL               | 44               | M   | IDH1MUT             |
| 5                    | III    | FrontalL               | 24               | M   | IDH1WT              |
| 6*                   | IV     | Parietal R             | 68               | M   | IDH1WT              |
| 7                    | IV     | FrontotemporoparietalL | 72               | M   | ND                  |
| 8                    | IV     | Occipital R            | 70               | M   | IDH1WT              |
| 9                    | IV     | TemporalL              | 67               | M   | IDH1MUT             |
| 10                   | IV     | TemporoparietalR       | 55               | M   | IDH1WT              |
| 11                   | IV     | TemporoparietalL       | 49               | M   | IDH1WT              |
| 12                   | IV     | OccipitalL             | 36               | M   | IDH1MUT             |
| 13                   | IV     | Frontal R              | 61               | F   | IDH1WT              |
| 14                   | IV     | Frontotemporal R       | 51               | F   | IDH1WT              |

\* Samples with analyzed blood; R = right, L = left; ND = not determined.

When grouping tumors grades I, II and III as one category and glioblastomas (grade IV) as another, we noticed that the first group predominantly harbored losses and deletions, while glioblastomas were characterized with more gains and amplifications. The average number of deletions and losses per I, II and III grouped tumors was 145 and per glioblastomas 32.8. The average number of gains and amplifications was 18.2 per first group tumors, and 36.3 per glioblastomas. Subsequent bioinformatics analyses denoted this as a visual trend that happened at higher thresholds but was not statistically relevant.

## 2.2. CNA in Pilocytic Astrocytomas (Grade I)

We assigned changes to the specific astrocytoma grade and found that patients with pilocytic astrocytomas (grade I) shared many jointly affected regions. Recurrent losses and recurrent gains are presented in Table 2. We noticed that the number of losses (21 losses) recurring in pilocytic cases exceeded the number of recurrent gains (two gains).

Furthermore, pilocytic astrocytomas showed distinct changes that were found in grade I tumors but not seen in grades II, III and IV. Such exclusive changes comprised only losses and they are shown in Table 3.

## 2.3. CNA in Diffuse Astrocytomas (Grade II)

When analyzing joint CNA for diffuse astrocytomas (grade II), we also found that samples shared specific common variations. It is obvious from Table 2 that the aberrant regions shared between grade II astrocytomas were less abundant than the number of aberrations found to be shared between grade I. The changes commonly found in grade II tumors included losses on chromosome cytobands 1p36.33–p11.2 and 1q21.1 and gains on 1q21.1–q25.1. Changes shared by grade II tumors were not found (repeated) in any of the grade I cases (Table 2).

We also sought for CNA aberrations exclusive for grade II tumors and found losses as well as gains as shown in Table 3.

Next, we decided to investigate whether any specific affected region appearing in any (either or whichever) grade I patient could also be found in any given grade II patient. By such approach we discovered that regions on chromosomes 17 and 19 were characteristic for low grade astrocytomas since they were shared by at least two low grade patients. More precisely, patients suffering from astrocytoma grade I or II shared losses on region 19q13.11–q13.43. In region 17q21.2–q21.31, one grade I tumor showed loss, while grade II gain.

## 2.4. CNA in Anaplastic Astrocytomas (Grade III) and Glioblastoma (Grade IV)

Unlike recurrent changes found in grade II tumors, the observed concurrent changes in grades III and IV tumors were numerous. There were altogether 127 CNA that could be found to recur across grades III and IV astrocytomas. They are listed in Table 2. It is interesting that both regions found to be affected in grade II astrocytomas, 1p36.33–p11.2 and 1q21.1, were also repeatedly affected in high grade tumors (Table 2).

CNA that were concurrent for pilocytic (grade I), anaplastic (grade III) and glioblastoma (grade IV) cases were: losses on 3q26.2; 4q28.2; 5q23.2; 6q13; 7p15.2 (gain and loss both); 10q11.21–q11.22; 10q21.3–q22.1; 11p15.4; 12p13.2 (deletion in high grades loss in pilocytic); 14q11.2; 14q13.1–q13.2; 15q11.1–q11.2; 18p11.22. Gains that were shared among I, III and IV grades were 7p15.2 and 15q11.1–q11.2. Those concurrent changes may indicate early events, since they were found both in low and high astrocytoma grades. Interestingly, region 17q22–q23.1 that lies within 17q11.1–25.3 was lost in grade I tumors, while the larger region 17q11.1–25.3 was gained in tumors with grades III and IV.

We noticed that grade III had an extensive number of exclusive aberrations consisting solely of losses and deletions without any specific gain or amplification. Exclusive grade III losses and deletions are shown in Table 3.

Glioblastomas (grade IV) also showed an extensive number of exclusive aberrations, even higher than the number found in other grades. Such unique CNA were losses and deletions, but also gains and amplifications and are listed in Table 3.

**Table 2.** Aberrant regions shared between astrocytomas of the same malignancy grade.

|                          | Grade I Astrocytoma  | Grade II Astrocytoma  | Grade III Astrocytoma and Grade IV Glioblastoma  |
|--------------------------|--|-----------------------|--|
| Recurrent losses         | 1p34.1; 1q25.2; 3q26.2; 4q28.1–q28.2; 5q23.2; 6q13; 6q25.1; 7p22.2–p22.1; 9p22.3; 10q11.21–q11.22; 10q21.3–q22.1; 11p15.4; 12p13.2; 12p11.21; 12q15; 14q11.2; 14q13.1–q13.2; 14q21.3–q22.1; 15q11.1–q11.2 *; 17q22–q23.2; 18p11.22 | 1p36.33–p11.2; 1q21.1 | 1p36.33–p35.2; 1p36.33–p36.32; 1p36.11–p35.3; 1q21.2; 1q44; 2p23.1–p22.3; 2p21; 2q33.3; 2q37.3; 3p26.3–p12.3; 3p21.31–p21.1; 3p14.3; 3q26.1; 3q29; 4q31.3; 5q23.2; 6p22.1; 6q13; 7q22.2; 8p23.1; 8p12; 8q21.13; 8q22.1; 9p24.3–p21.1; 9p21.3–p13.3; 9q33.3; 9q34.11; 10p15.3–p11.1; 10q11.21–q26.3; 10q21.3–q22.1; 10q23.32–q23.33; 10q26.11–q26.13; 10q26.3; 11p15.4; 11q13.2–q13.3; 13q13.3; 13q14.11–q14.13; 13q22.1; 14q11.2–q21.2; 14q13.1–q13.2; 14q23.2–q23.3; 15q11.1–q11.2; 15q21.2; 16q22.1; 17q12–q21.32; 18q12.1; 21q22.12–q22.13; 22q11.1–q13.33; 22q12.1–q12.2; 22q12.2–q12.3; 22q13.1; 22q13.1–q13.2; Xp22.33; Xq12 |
| Recurrent gains          | 7p15.2; 15q11.1–q11.2 *  | 1q21.1–q25.1          | 1p36.33–p11.2; 1p31.1; 1q21.1–q44; 2q31.1; 3q27.1; 4p16.1; 4q31.21; 5p12; 7p22.3–p11.2; 7p15.2; 7q11.21–q36.3; 8p11.22; 8q24.3; 10p12.2; 10q26.3; 11p15.5; 11q13.1; 14q11.2; 14q21.1; 14q32.2; 14q32.33; 15q11.1–q11.2; 15q22.31; 16p13.3; 16q22.1; 17p13.1; 17q11.1–q25.3; 17q21.32; 17q25.3; 19p13.3; 19p13.2; 19p13.12; 19q11–q13.43; 19q13.11; 19q13.42; 20p13–p11.1; 20q11.21–q13.33; 22q12.2; 22q13.2; 22q13.31  |
| Recurrent deletions      | -  | -                     | 1p31.1; 5p15.33 **; 9p21.3; 12p13.31; 22q11.23   |
| Recurrent amplifications | -  | -                     | 3q26.1 ***; 7p11.2   |

\* One sample showed gain while the other one loss of the same region; \*\* one sample showed deletion while the other one loss of the same region; \*\*\* one sample showed amplification while the other one gain of the same region.

**Table 3.** Exclusive changes found in different grades of astrocytomas.


|                           | Grade I Astrocytomas   | Grade II Astrocytomas   | Grade III Astrocytomas  | Grade IV Glioblastomas   |
|---------------------------|--|---|---|--|
| Exclusive losses          | 1p34.1; 1q25.2; 6q25.1;<br>7p22.2–p22.1; 9p22.3; 12p11.21;<br>12q15; 14q21.3–q22.1 | 1q31.2; 2q31.1; 2q37.3; 3p21.31;<br>5q31.3; 6p22.3; 19p13.3–p13.2;<br>21q22.3   | 1q24.2; 1q24.3; 1q41; 1q42.13; 1q42.2; 2p25.3; 2p25.1;<br>2p24.1; 2p23.3; 2p22.3; 2p14; 2p13.3; 2q31.1; 2q33.3;<br>2q37.2; 2q37.3; 3q26.32; 4p16.3; 4p16.1; 4p15.33; 4p12;<br>4q13.3; 4q25; 4q26; 4q32.3; 4q34.1; 5p13.2; 5q11.2;<br>5q14.1; 5q14.3; 5q23.1; 5q31.3; 5q32; 6p25.3;<br>6p22.2–p22.1; 6p12.3; 6q16.1; 6q21; 6q24.1; 6q25.1;<br>6q25.3; 7q11.23; 8p23.2; 8p21.28q21.3; 8q22.2; 9p21.1;<br>9q21.13; 9q22.31; 9q31.1; 9q33.3; 10p14; 10p12.31;<br>10q22.1; 10q24.32; 10q25.1; 10q26.13; 11p14.3;<br>11q13.1; 11q14.1; 11q14.3; 11q23.2–q23.3; 11q23.3;<br>11q24.2; 11q24.3; 12q13.11; 12q21.31; 12q22;<br>13q33.3–q34; 14q22.1; 14q23.1; 14q23.3; 14q24.3;<br>14q31.3; 14q32.33; 17p11.2; 17q12; 17q21.32; 17q21.33;<br>17q24.2; 17q24.3; 17q25.3; 19p13.2; 19p13.11;<br>19q13.12; 19q13.2; 20p12.3; 20p12.1; 22q12.3; 22q13.1 | 2p11.2; 3q22.2; 3q26.31; 4p16.1; 5p15.32–p15.3;<br>6p25.1; 10q21.2; 10q23.2–q23.31; 10q24.2–q24.33;<br>11p15.1; 11q12.2; 11q12.2–q13.1; 13q31.1;<br>13q31.3–q32.1; 14q13.1; 14q23.3; 15q26.1;<br>22q13.31–q13.33; Xq27.1–q27.3; Xq27.3   |
| Exclusive gains           | -  | 1q31.1; 3p21.31–p21.2; 5q35.3;<br>6p25.3; 6p25.2; 6p22.1, 6p21.1,<br>8p23.1, 11q13.4, 12q13.11,<br>12q14.1, 15q13.3, 15q24.3–q25.1;<br>17p13.3, 17p11.2, 18q12.2;<br>22q11.23–q12.1 | -   | 2p25.3; 2q21.1; 2q35; 3q26.32–q27.3; 3q29; 4p11; 4q23;<br>4q31.21; 5p15.31; 5p15.31–p15.2; 5p14.3; 5p14.1;<br>5p13.2; 5p12; 5q12.3; 5q23.1; 5q35.3; 6p22.3; 6q25.3;<br>6q27; 7p12.1–p11.2; 7q21.13–q21.3; 7q22.1; 7q36.1;<br>7q36.3; 8p23.1; 8p11.23; 8q24.3; 9q22.1; 9q22.2;<br>10p12.31; 10q24.1; 10q24.31; 11q13.2; 11q23.1–q23.2;<br>11q23.3; 11q24.2; 12p13.32; 14q32.2; 14q32.33;<br>15q11.2; 15q22.31; 17q11.2; 17q12; 17q21.31; 17q25.1;<br>18q23; 19p13.2; 19q13.11; 19q13.32; 20q13.13; 21q22.2;<br>22q11.21; 22q12.2; 22q13.1; 22q13.2; Xp22.33;<br>Xp22.11; Yp11.32; Yp11.31–p11.2 |
| Exclusive deletions       | -  | -   | 2q11.2; 2q12.1; 5q35.1; 6p22.1; 8p23.1; 8q12.3; 8q24.3;<br>12q13.13.  | 2p22.3; 2q22.1; 2q32.1; 4q13.2; 5q34; 6p21.31–p21.2;<br>6q14.1; 9p21.3; 10q21.3; Xp11.23; Xq28   |
| Exclusive amplificati-ons | -  | -   | -   | 3q26.1–q26.2; 4q12; 7p21.3–p21.2; 7p12.3; 7p12.2;<br>7p12.1; 7p11.2; 7q31.1–q31.2; 7q35; 10q26.3; 14q21.1;<br>20q12–q13.11; Xq22.3   |

### 2.5. Assigning the Most Frequently Aberrant Regions

We were also interested in how often specific regions were concurrent in our total astrocytoma patients. Therefore, we searched for most frequently aberrant regions shared among the highest number of investigated patients. We defined the region as frequent when the same CNV was detected in three or more patients.

Four patients shared losses on 3p26.3–p12.3; 3q26.1; 10q11.21–q26.3; 13q14.11–q14.13; 22q13.1; five patients shared losses on 9p24.3–p11.2; 9p21.3; 9p21.3–p13.3; 10p15.3–p11.1; 12p13.31; 22q11.23; and seven patients shared losses on 14q11.2.

Gains that three or more patients had in common were as follows: four patients shared gains on chromosome 2q31.1; 4p16.1; 7p15.2; 8q24.3; 11p15.5; 17p13.1; 17q25.3; 19p13.2; 19q11–q13.43; 19q13.42; 20q11.21–q13.33; five patients shared gains on 7q11.21–q36.3; 7p22.3–p11.2; 8p11.22; 10p12.2; 14q11.2; 15q11.1–q11.2. We presumed that those regions could harbor genes important for glial tumorigenesis. The regions with highest frequencies are shown in Figure 1.



**Figure 1.** Frequent aberrant regions shared among the highest number of investigated patients.

### 2.6. Broad Regions

It has been shown that gliomas can display both focal and broad aberrations of their genome [15]. Therefore, we also decided to assess the regions showing broad changes. The analysis was performed by the following criteria: minimum log ratio for gains is 0.25 and for losses  $-0.25$ , minimal size of CNAs 2Mb and minimum number of consecutive probes 3. The list of broad aberrations found in our investigated group of astrocytomas is shown in Table 4.



**Table 4.** The regions showing broad changes.

| Chromosome | Regions   | Change | WHO Grade      | References    |
|------------|---|--------|----------------|---------------|
| 1          | chr1p36.33–p11.2; chr1p36.33–p36.32;<br>chr1p36.33–p35.2  | Loss   | AII; AIII; 2XG | [12,15,22,23] |
| 1          | chr1p36.33–p11.2  | Gain   | 2XG            |               |
| 1          | chr1q21.1–q25.1; chr1q21.1–q44                            | Gain   | AII; G         | [19]          |
| 3          | chr3p26.3–p12.3   | Loss   | 4XG            | [19,24]       |
| 3          | chr3q26.32–q27.3; chr3q26.2–q29                           | Gain   | 2XG            | [19]          |
| 5          | chr5p15.31–p12; chr5p15.33–p11                            | Gain   | 2XG            | [16,19]       |
| 7          | chr7  | Gain   | 7XG            | [15,23]       |
| 9          | chr9p24.3–p21.3   | Loss   | 6XG            | [19,23]       |
| 10         | chr10p15.3–p11.1  | Loss   | 4XG            | [19]          |
| 10         | chr10q23.1–q26.3; chr10q11.21–q26.3;<br>chr10q24.2–q24.33 | Loss   | 4XG            | [19,23]       |
| 13         | chr13q21.2–q31.1; chr13q12.11–q31.3                       | Loss   | AIII; G        | [19,23]       |
| 16         | chr16p13.3–p11.2; chr16p13.11–p12.1;<br>chr16p12.3–p11.2  | Loss   | AI; 2XG        | [19]          |
| 17         | chr17q11.1–q25.3  | Gain   | 2XG            | [23]          |
| 19         | chr19p13.3–p12  | Gain   | 4XG            | [19]          |
| 19         | chr19q11–q13.43   | Gain   | 3XG            | [12,19]       |
| 20         | chr20p13–p11.1  | Gain   | 3XG            | [25]          |
| 20         | chr20q11.21–q13.33  | Gain   | 3XG            | [19]          |
| 22         | chr22q11.21–q13.33  | Loss   | 3XG            | [19]          |

AI = astrocytoma grade I; AII = astrocytoma grade II, AIII = astrocytoma grade III, G = glioblastoma.

Seven glioblastoma patients harbored amplification of chromosome 7 (trisomy of the whole chromosome 7) (Table 4). Benign pilocytic astrocytomas lacked any of the listed changes.

## 2.7. CNA in Autologous Blood Sample DNA


Since aCGH uses a reference genome on a chip obtained from a pool of healthy individuals, we were interested in whether some of the changes found could be attributed to specific population polymorphisms and not to aberrations. To ascertain whether some of the variations were of the constitutive nature, we also analyzed the autologous blood samples of two patients by comparing it to the reference DNA on the chip. The blood samples were from one patient suffering from pilocytic and the other from glioblastoma. Neither of the two autologous blood samples harbored broad aberrations that are shown in Table 4. Autologous blood DNA from pilocytic astrocytoma sample showed altogether 23 copy number changes of which there were three amplifications, eight gains, nine losses and three deletions. The majority of changes (68%) from autologous constitutive DNA were repeated in the belonging tumor DNA (15/22), which may indicate individual or population CNV, but also an inborn susceptibility. Four amplifications and three deletions were exclusive for the blood DNA indicating probable population genetic variation.

Interestingly, all alterations noted for normal blood DNA from glioblastoma patient were repeated in the DNA of the belonging tumor, so there were no exclusive changes for autologous blood DNA of the tested glioblastoma patient. Shared alterations for tumor and blood DNA of this glioblastoma patient were three amplifications, six gains, nine losses and three deletions.

## 2.8. Functional Analysis by GISTIC2.0.23 Identified Significant Genomic Targets in Astrocytomas

With the objective to interpret and draw conclusions from our raw data and results, we performed bioinformatics analyses. GISTIC identifies those regions of the genome that are aberrant more often

than would be expected by chance. Greater weight is given to high amplitude gains or deletions that are less likely to represent random aberrations [15]. The GISTIC algorithm identifies likely somatic driver copy number CNA by evaluating the amplitude and frequency of either amplified or deleted observation [26]. To find statistically relevant recurrent CNA, GISTIC determined focally amplified (red) and deleted (blue) regions plotted along the genome (Figure 2).



**Figure 2.** Heat map images of four different intracranial astrocytic brain tumor sample pools based on total segmented DNA copy number variation profiles. Images were analysed using GISTIC (v2.0.23). In each heat map, the samples are arranged from left to right, and chromosome arrangement flows vertical, top to bottom ordering. Red represents CN gain and blue represents CN loss. (A) all samples; (B) malignant samples; (C) high grade samples; (D) low grade samples.

Furthermore, GISTIC v2.0.23 was also used to identify significant amplification and deletion events assigned to malignancy grades. To this end, we computed GISTIC CNA amplification/deletion plots, segmented CN heat plots and identify genes within those regions. Moreover, we utilized a range of cutoff values in the analysis to identify segments of significance.

## 2.9. Results on Total Sample Analysis

The results of GISTIC algorithm analysis identified regions of aberration that are more likely to drive cancer pathogenesis. A number of regions of recurrent CN gains and losses have been identified across all samples. Their genomic locations including the number of the associated genes as a function of the corresponding  $q$ -value cutoff criterion is summarized in Table 5.

**Table 5.** List of regions and their associated genes located in the most common sections of recurrent DNA CNAs, derived from analysis conducted on our total astrocytic brain tumor sample.

| Focal Event   | Cytoband | $q$ -Value | Genomic Position (hg19)    | 0.45 | 0.35 | 0.25 | 0.15 | 0.05 |
|---------------|----------|------------|----------------------------|------|------|------|------|------|
| Amplification | 3q28     | 0.36509    | chr3: 169432744–198022430  | 217  | 0    | 0    | 0    | 0    |
| Amplification | 4p16.3   | 0.36509    | chr4: 1309269–1885110      | 10   | 0    | 0    | 0    | 0    |
| Amplification | 8q24.3   | 0.36509    | chr8: 144884270–146364022  | 62   | 0    | 0    | 0    | 0    |
| Amplification | 12q13.3  | 0.36509    | chr12: 57863606–58162220   | 20   | 0    | 0    | 0    | 0    |
| Amplification | 12p13.32 | 0.36509    | chr12: 3736374–4718832     | 9    | 0    | 0    | 0    | 0    |
| Amplification | 14q32.33 | 0.36509    | chr14: 106400482–107349540 | 3    | 0    | 0    | 0    | 0    |
| Amplification | 17q25.3  | 0.36509    | chr17: 78847437–79535591   | 25   | 0    | 0    | 0    | 0    |
| Amplification | 21q22.3  | 0.36509    | chr21: 46788100–46974713   | 3    | 0    | 0    | 0    | 0    |
| Amplification | 22q13.33 | 0.36509    | chr22: 50033682–51304566   | 40   | 0    | 0    | 0    | 0    |
| Total         |          |            |                            | 389  | 0    | 0    | 0    | 0    |
| Deletion      | 17p13.2  | 0.0027597  | chr17: 1–7172830           | 176  | 176  | 176  | 176  | 213  |
| Deletion      | 9p21.3   | 0.024206   | chr9: 21030772–22655576    | 27   | 27   | 27   | 34   | 34   |
| Deletion      | 13q12.11 | 0.024206   | chr13: 19891479–20000549   | 1    | 1    | 1    | 1    | 1    |
| Deletion      | 22q12.3  | 0.037797   | chr22: 28350866–44221419   | 261  | 261  | 261  | 261  | 261  |
| Deletion      | 10q24.2  | 0.059906   | chr10: 93786297–105364688  | 171  | 171  | 171  | 178  | 0    |
| Deletion      | 15q15.1  | 0.059906   | chr15: 40736349–42074646   | 33   | 33   | 33   | 33   | 0    |
| Deletion      | 16q22.1  | 0.059906   | chr16: 66967463–74334046   | 130  | 130  | 130  | 138  | 0    |
| Deletion      | 17q21.31 | 0.059906   | chr17: 36996467–45200422   | 255  | 255  | 255  | 255  | 0    |
| Deletion      | 20q11.22 | 0.059906   | chr20: 6031411–36620782    | 240  | 240  | 240  | 240  | 0    |
| Deletion      | 14q12    | 0.15415    | chr14: 1–47314894          | 232  | 235  | 235  | 0    | 0    |
| Deletion      | 3p14.3   | 0.15415    | chr3: 57198280–58186818    | 9    | 9    | 9    | 0    | 0    |
| Deletion      | 5q23.2   | 0.15415    | chr5: 125909127–126208712  | 3    | 3    | 3    | 0    | 0    |
| Deletion      | 12q21.33 | 0.15415    | chr12: 31143267–133851895  | 879  | 879  | 879  | 0    | 0    |
| Deletion      | 11p15.4  | 0.2165     | chr11: 9277720–9686181     | 6    | 6    | 6    | 0    | 0    |
| Total         |          |            |                            | 2423 | 2426 | 2426 | 1316 | 509  |

For exploratory reasons and with conscious danger of over-interpreting our results by including anecdotal structural changes, we decided to investigate CNA by lowering the cutoff of  $q$ -values. We utilized a range of cutoff values in the analysis to identify segments of significance. Such more permissive approach revealed some additional relevant regions. The results are presented in Table 5.

By focusing on a 0.25 ( $q$ -value) criterion, no significant amplifications were detected, while, at the same threshold level, significant deletions affected 14 chromosomal regions, out of which 4 (17p13.2, 9p21.3, 13q12.11, 22q12.3) remained significant even at 0.05  $q$ -value cutoff level, all with GISTIC scores higher than 55.

## 2.10. Results of Malignant Astrocytoma Analysis (Grade I Pilocytic Cases Excluded)

Computational analysis using GISTIC was repeated as previously described. However, this reanalysis excluded benign astrocytoma cases. Such approach resulted in three novel, previously disregarded regions at  $q$ -value threshold of 0.25 to be identified as significantly amplified (3q28, 14q32.33, 18q12.2), while the number of significantly deleted regions decreased by more than a half (from 14 to 6). Two of those (17p13.2, 9p21.3) still remained significant at a threshold level of  $q$ -value = 0.05. Out of six remaining regions, four overlapped with those in the previous analysis (17p13.2, 13q12.11; 10q24.2, 9p21.3). The region 14q32.33 found to be amplified on the total sample at  $q$ -0.45 was amplified in malignant cases at  $q$ -0.25. Table 6 and Figure 2B summarize the obtained result.

**Table 6.** List of regions and their associated genes located in the most common sections of recurrent DNA CNAs, derived from analysis conducted on malignant astrocytic brain tumor samples. Benign cases were excluded.

| Focal Event   | Cytoband | q-Value   | Genomic Position (hg19)    | Gene Count (q-Value Cutoff) |      |      |      |      |
|---------------|----------|-----------|----------------------------|-----------------------------|------|------|------|------|
|               |          |           |                            | 0.45                        | 0.35 | 0.25 | 0.15 | 0.05 |
| Amplification | 3q28     | 0.18103   | chr3: 169432744–198022430  | 217                         | 217  | 217  | 0    | 0    |
| Amplification | 14q32.33 | 0.18103   | chr14: 106400482–107349540 | 3                           | 3    | 3    | 0    | 0    |
| Amplification | 18q12.2  | 0.18103   | chr18: 34934984–35256171   | 3                           | 3    | 3    | 0    | 0    |
| Amplification | 1p36.32  | 0.26407   | chr1: 2215776–2801808      | 14                          | 14   | 0    | 0    | 0    |
| Amplification | 4p16.3   | 0.26407   | chr4: 1309269–1885110      | 10                          | 10   | 0    | 0    | 0    |
| Amplification | 8q24.3   | 0.26407   | chr8: 144884270–146364022  | 62                          | 62   | 0    | 0    | 0    |
| Amplification | 12q13.3  | 0.26407   | chr12: 57863606–58162220   | 20                          | 20   | 0    | 0    | 0    |
| Amplification | 12p13.32 | 0.26407   | chr12: 3736374–4718832     | 9                           | 9    | 0    | 0    | 0    |
| Amplification | 20q13.33 | 0.26407   | chr20: 61784176–63025520   | 55                          | 55   | 0    | 0    | 0    |
| Amplification | 21q22.3  | 0.26407   | chr21: 46788100–46976402   | 3                           | 3    | 0    | 0    | 0    |
| Amplification | 22q13.33 | 0.26407   | chr22: 50033682–51304566   | 40                          | 40   | 0    | 0    | 0    |
| Total         |          |           |                            | 436                         | 436  | 223  | 0    | 0    |
| Deletion      | 17p13.2  | 0.0047853 | chr17: 1–7172830           | 176                         | 176  | 176  | 176  | 176  |
| Deletion      | 9p21.3   | 0.0068152 | chr9: 20621756–25684739    | 34                          | 34   | 34   | 34   | 34   |
| Deletion      | 10q24.2  | 0.058622  | chr10: 93783434–105364688  | 171                         | 171  | 171  | 178  | 0    |
| Deletion      | 14q21.3  | 0.058622  | chr14: 48262357–51191843   | 20                          | 20   | 20   | 20   | 0    |
| Deletion      | 1p36.11  | 0.23541   | chr1: 24991120–31189272    | 97                          | 97   | 97   | 0    | 0    |
| Deletion      | 13q12.11 | 0.23541   | chr13: 1–38115337          | 119                         | 119  | 119  | 0    | 0    |
| Total         |          |           |                            | 617                         | 617  | 617  | 408  | 210  |

### 2.11. The Results of High Grade Sample Analysis (Grades III and IV)

By excluding low grade samples (grades I and II) and repeating the analysis on high grade samples including the most aggressive type glioblastoma (grade IV), none of the previously identified amplified regions, classified as statistically significant at a 0.25 *q*-value threshold, were observed. On the other hand, all previously identified deletions on a malignant group were still present, constituting a stable result when it comes to the identified deletion events (Table 7, Figure 2C). By increasing the cutoff value from 0.25 to 0.35, significant amplifications become evident and in line with three of the previously identified ones, 3q28; 12q13.3 and 21q22.3. One of which (3q28) was significant at a 0.25 threshold for malignant astrocytoma group and at *p*-0.45 threshold level on our total analyzed sample, thus in line with the assumed, stable cross sample identified amplification region.

**Table 7.** List of regions and their associated genes located in the most common sections of recurrent DNA CNAs, derived from analysis conducted involving high grade samples (grades III and IV).

| Focal Event   | Cytoband | q-Value  | Genomic Position (hg19)   | Gene Count (q-Value Cutoff) |      |      |      |      |
|---------------|----------|----------|---------------------------|-----------------------------|------|------|------|------|
|               |          |          |                           | 0.45                        | 0.35 | 0.25 | 0.15 | 0.05 |
| Amplification | 3q28     | 0.29658  | chr3: 169432744–198022430 | 217                         | 217  | 0    | 0    | 0    |
| Amplification | 12q13.3  | 0.29658  | chr12: 57863606–58210057  | 24                          | 24   | 0    | 0    | 0    |
| Amplification | 21q22.3  | 0.29658  | chr21: 46788100–46974713  | 3                           | 3    | 0    | 0    | 0    |
| Total         |          |          |                           | 244                         | 244  | 0    | 0    | 0    |
| Deletion      | 9p21.3   | 0.049849 | chr9: 20621756–25684739   | 34                          | 34   | 34   | 34   | 34   |
| Deletion      | 17p13.2  | 0.05166  | chr17: 1–7172830          | 176                         | 176  | 176  | 176  | 0    |
| Deletion      | 10q24.2  | 0.051797 | chr10: 93783434–105367017 | 171                         | 171  | 171  | 178  | 0    |
| Deletion      | 14q21.3  | 0.051797 | chr14: 48262357–51191843  | 20                          | 20   | 20   | 20   | 0    |
| Deletion      | 1p36.11  | 0.21828  | chr1: 24995465–31189272   | 97                          | 97   | 97   | 0    | 0    |
| Deletion      | 13q12.11 | 0.21828  | chr13: 21324433–21947432  | 5                           | 5    | 5    | 0    | 0    |
| Total         |          |          |                           | 503                         | 503  | 503  | 408  | 34   |

### 2.12. The Results of Low Grade Samples Analysis (Grades I and II)

The last computation in this GISTIC utility series was the analysis involving low grade samples (AI and AII). Table 8 and Figure 2D contain the obtained result. The lack of significant deletions, as well as of amplifications was evident at *q*-value of 0.25.

**Table 8.** List of regions and their associated genes located in the most common sections of recurrent DNA CNAs, derived from analysis conducted involving low grade samples (grades I and II).

| Focal Event | Cytoband | q-Value | Genomic Position (hg19)  | Gene Count (q-Value Cutoff) |      |      |      |      |
|-------------|----------|---------|--------------------------|-----------------------------|------|------|------|------|
|             |          |         |                          | 0.45                        | 0.35 | 0.25 | 0.15 | 0.05 |
| Deletion    | 3p14.3   | 0.44232 | chr3: 57198280–58187545  | 9                           | 0    | 0    | 0    | 0    |
| Deletion    | 5q21.2   | 0.44232 | chr5: 1–180915260        | 1050                        | 0    | 0    | 0    | 0    |
| Deletion    | 11p15.4  | 0.44232 | chr11: 1–135006516       | 1478                        | 0    | 0    | 0    | 0    |
| Deletion    | 13q12.11 | 0.44232 | chr13: 1–38110402        | 119                         | 0    | 0    | 0    | 0    |
| Deletion    | 15q15.1  | 0.44232 | chr15: 40735035–42074637 | 33                          | 0    | 0    | 0    | 0    |
| Deletion    | 16q22.2  | 0.44232 | chr16: 66967005–75040923 | 138                         | 0    | 0    | 0    | 0    |
| Deletion    | 17q12    | 0.44232 | chr17: 1–64211652        | 1112                        | 0    | 0    | 0    | 0    |
| Deletion    | 18q21.1  | 0.44232 | chr18: 43535382–43924106 | 4                           | 0    | 0    | 0    | 0    |
| Deletion    | 20q11.22 | 0.44232 | chr20: 6027505–36613689  | 240                         | 0    | 0    | 0    | 0    |
| Deletion    | 22q12.3  | 0.44232 | chr22: 28346538–44221618 | 261                         | 0    | 0    | 0    | 0    |
| Total       |          |         |                          | 4444                        | 0    | 0    | 0    | 0    |

To sum up the results of GISTIC 2.0.23 analysis of CN profiles above, we can point out that regions identified as significantly deleted in high grade samples were: 9p21.3; 17p13.2; 10q24.2; while regions 14q21.3; and 1p36.11 surfaced only in malignant cases indicating their involvement as later events.


Regions significantly amplified and connected to pronounced malignancy were 3q28; 12q13.3 and 21q22.3, of which the last two emerged only in high grade cases, while 3q28 was constantly found. None of the above aberrations were significant in low grade astrocytoma tumors. Regions 17q25.3 and 8q24.3 that were significantly amplified on our total sample did not emerge in subsequent analyses and therefore may be characteristic for lower grade astrocytomas. Of note is that deletions 3p14.3; 11p15.4; 15q15.1; 16q22.1; 20q11.22 and 22q12.3 were all found in low grade samples at a threshold level of  $q$ -0.45 and also on our total sample at  $q$ -0.25, but were not repeatedly found in high grades. These findings indicate that these regions and genes within may also be involved as early events.

### 2.13. Computing GISTIC Heat Maps for the Previous Analyses

Chromosomal alterations based on DNA CN changes in all four case studies are illustrated using heat maps (Figure 2). Upon visual inspection, a clear distinction between low and high grade samples is evident, with high grade samples closely reflecting the general heat map images of the entire batch (Figure 2B,C). Moreover, an almost systematic amplification of segments across majority of samples in chromosome 7 and respective deletion in chromosome 10 could be observed.

### 2.14. Assessing Functional Features of Genes Identified by GISTIC (Relevant Annotated Genes)

The most significant amplifications and deletions identified by GISTIC were further investigated using functional enrichment strategies as implemented in DAVID. Out of 840 CNA associated genes, according to DAVID, 81 were not linked to any known pathway or function based annotation category. Of the remaining 759 associated, only 65 genes assigned to a pathway or a functional category were significantly over-represented (Bonferroni and BH adjusted  $p$ -value < 0.05) via gene annotation within the identified CNAs. Figure 3 summarizes the distribution of those 65 identified genes across different enrichment categories as well as the information regarding their shared contribution to each of the indicated individual categories. The list of the associated 65 genes is included in Table 9, while, in Table S1, their distribution across cytobands with corresponding significance metrics can be found.



**Figure 3.** Matrix layout for all 65 genes across 35 functional categories (association calculated by DAVID), sorted by size. Dark circles in the matrix indicate functional categories with genes that are part of the intersecting groups, that is, are associated with each category of the set. The bar plot above the matrix depicts the number of shared genes, while the horizontal bar plot on the left reflects the number of genes within each group. Blue and red colored bars indicate the respective aberration.

**Table 9.** List of genes within CNAs associated with significantly enriched functional categories as calculated using DAVID computational strategy (Bonferroni and BH adjusted  $p$ -value threshold set to  $\alpha = 0.05$ ).


| Gene ID   |
|---|
| AHSG, ATP13A3, ATP13A4, ATP13A5, BLNK, C1QBP, CCNA1, CHUK, CLDN7, CLEC10A, CXCL16, ENTPD1, FCN3, FETUB, FGF8, FGF9, FGR, FLT1, FLT3, GABARAP, GP1BA, HHEX, HMGB1, HPS6, HRG, HTR3C, HTR3D, HTR3E, IFI6, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNW1, IL17D, KNG1, NFKB2, NLRP1, P2RX1, P2RX5, PIK3AP1, POLR1D, RFXAP, RTN4RL1, SMPDL3B, SOS2, SRSF4, TAF5, TNFRSF19, TRIM8, XAF1, YTHDF2, YWHAE, ZNF683 |

## 2.15. Signaling Pathways Involved

To further elevate specificity of our analysis, we restricted our functional pathway analysis to that contained within a KEGG database performing the enrichment analyses with  $p < 0.05$  as a cutoff criterion. As a result, only genes associated with deleted segments were significantly enriched in 18 out of 325 total Homo sapiens associated KEGG pathways.

Figure 4 illustrates this result indicating a PI3K-Akt signaling pathway, cytokine–cytokine receptor interaction, the nucleotide-binding oligomerization domain (NOD)-like receptor, Jak-STAT, retinoic acid-inducible gene (RIG)-I-like receptor signaling pathways, Toll-like receptor pathway and pathways involved in HPV, herpes simplex and hepatitis infection were the most significantly represented in terms of the number of genes identified by GISTIC. Several pathways involved in inflammation—necroptosis, Cytosolic DNA-sensing pathway, and Natural killer cell mediated cytotoxicity were also represented.





**Figure 4.** Enrichment analysis utilizing the KEGG pathway database. Analysis included genes from all malignant samples associated with both deleted and amplified regions. No significant enrichment was associated with amplified segments.

To further investigate the role of these genes, we plotted the enrichment map (Figure S1), revealing roughly equal systematic involvement of all genes across the identified pathways.

To see how many of the identified genes and across how many KEGG pathways underlined the enriched pathways, we performed the set intersection analysis (Figure S2). The obtained result confirms previous indications asserting 12 out of 44 KEGG associated genes to be shared among 18 significantly enriched pathways.

Finally, we extracted the most important identified KEGG pathways shown in Figure S3 and labeled genes associated with deleted chromosomal regions.

### 3. Discussion

In the present investigation, we wanted to elucidate which chromosomal regions and annotated genes are involved in the genesis and progression of astrocytic brain tumors. Cancer genomes suffer many structural changes [5] and CNAs have been commonly found in glioma [19]. However, CNAs differ in their frequency of recurrence even among the patients suffering from the same type of malady. Which specific CNAs are attributed as early events and which are responsible for progression still remains to be fully understood.

In our total sample, we found that the number of losses significantly exceeded the number of observed gains and amplifications. This finding is not unusual since it has been reported as a general pattern in cancer [27] that losses are more frequent than amplifications. Furthermore, we have found that the mean number of CNA is much higher in malignancy grades III and IV when compared to lower grades. In addition, a great number of aberrant regions were recurring in grades III and IV.

Our study also revealed similarities and differences in the aberrations across astrocytoma grades. The CNA that were found to be shared among grade I benign pilocytic astrocytomas indicated relatively different patterns than observed in the malignant group. It has been postulated that pilocytic astrocytomas differ from other histopathological types as they are slow-growing and non-infiltrative. Although they usually exhibit a normal karyotype, ~32% display chromosomal abnormalities. Chromosomal regions that have been reported to hold abnormalities include 1p, 2p,

4q–9q and 13q and losses on 1p, 9q, 12q and 19–22 [28–32]. The situation found in our study is compatible to some of the aberrations reported previously, but also differed from the literature. We found losses in pilocytic astrocytomas of which: 3q; 10q; 11p; 12p; 14q; 15q and 18p have not previously been reported, while there were fewer gains found in our study, only on 7p15.2 and 15q11.1–q11.2.

Grade II astrocytomas harbored very few recurrent aberrations, only losses on 1p36.33–p11.2 and 1q21.1 and gains on 1q21.1–q25.1. None of them recurred in grade I tumors. However, regions with recurrent losses in grade II astrocytomas were also repeatedly affected in higher grade tumors.

Malignant high grades tumors, III and IV, on the other hand, harbored numerous recurrent changes, which indicates the augmentation of aberrations as the disease progresses.

The majority of CNA that have been reported in the literature were also discovered and confirmed with our experiments [24,25]. However, the frequencies differed as well as their previous assignments to specific grade. Seifert et al. [33] in their computational study revealed similarities and differences in gene expression levels between astrocytomas of all four WHO grades. The authors report that transcriptional alterations of individual signaling pathways typically increase with WHO grade of astrocytoma. The high number of copy number changes found to be increasing with the grade can also be indicative of the acquisition of genomic instability in glioblastoma, especially since deleted regions may harbor genes involved in mismatch DNA repair.

The most common amplification—the one on chromosome 7 [8,22], was also frequently found in our investigated sample with 77.8% of tumors displaying this type of change. Another frequent event—deletions of chromosome 10 [22]—has been discovered in 88.9% of our patients. This finding, which is in accordance with literature and included loss of heterozygosity on chromosomal arm 10p, is commonly reported for high-grade gliomas, usually concentrated in the region 10p14–p15 [4,34]. Our study found losses of 10p11.1–p15.3 region in 77.8% of glioblastomas.

Brennan et al. [8] found higher frequencies of the common amplification events reported for astrocytoma than other investigators. However, such frequencies were not confirmed in our study. Only 22.2% of our cases had gains on chromosome 12 (CDK4 and MDM2), and 28.6% on chromosome 4 (PDGFRA).

Several of our results corroborate the findings of previous studies regarding relevant genes [8,35]. We found *EGFR* amplification to be targeted in 89% of glioblastomas and one astrocytoma grade II, with a total of 90% of cases with amplified *EGFR* genes.

In order to comprehend CNA events in astrocytomas of different pathohistological types and identify alterations that are biologically and functionally significant, we used the GISTIC algorithm. We were interested in differentiating founder events and subclonal drivers from passenger mutations [2,36]. The software was utilized previously in numerous cancer studies, including lung [37], colorectal carcinoma [38] and melanoma [39], and has facilitated the identification of new significant cancer associated targets.

By exploring a range of cutoff *q*-values, we identified additional segments of significance. Thus, significant deletions affecting 14 chromosomal regions were found, out of which deletions of 17p13.2, 9p21.3, 13q12.11 and 22q12.3 remained significant even at 0.05 *q*-value. Of importance is that locus 9p22.1–p21.3 (p16INK4a/p14ARF/p15INK4b) has been known to encompass the *CDKN2A* gene frequently deleted in gliomas [23]. Furthermore, other regions also harbored important genes, *RB* gene in the region 13q and *TP53* gene in 17p13. In accordance with our findings is the study by Yin et al. [23], who found that the long arm of chromosome 13 was lost in nearly 50% of cases.

Low grade astrocytomas demonstrated the lack of both significant deletions and amplifications, suggesting a general pattern associated with these grades. Common genetic changes and tumor associated mutations found in higher grade gliomas, p53, *PDGF*, p16 (*CDKN2A*), *IDH1* and *IDH2* are rarely reported in pilocytic astrocytomas, which is consistent with our results that also indicate a lack of focal abnormalities in loci where those genes reside.

When excluding pilocytic cases, the GISTIC reanalysis resulted in three novel, previously disregarded regions to be identified as significantly amplified, 3p28, 14q32.33 and 18q12.2. Since



the number of significantly deleted regions decreased by more than a half, it seems that deletions are characteristic of benign cases. Two of the deleted regions, 17p13.2 and 9p21.3, still remained significant at a threshold level of  $q$ -value 0.05. Out of six remaining regions, four overlapped with those in the previous analysis (17p13.2, 13q12.11; 10q24.2, 9p21.3). We can assume that these regions could represent the early events in the consecutive steps of gliomagenesis. Of note is that the region 14q32.33 found to be amplified on a total sample at  $q$ -0.45 was in malignant cases amplified at  $q$ -0.25.

In the analysis performed only on high grade astrocytomas (III and IV), none of the previously identified amplified regions, classified as significant at a 0.25  $q$ -threshold, were observed. On the other hand, all previously identified deletions found in malignant groups were present, constituting a stable result. When the cutoff value was raised to 0.35, significant amplifications became evident and, in line with three previously identified ones of which 3q28 was significant at a 0.25 threshold for a malignant astrocytoma group and at  $p$ -0.45 on our total sample. This is in line with the identified stable cross sample amplification region. Thus, the significantly deleted regions in high grade astrocytoma groups were: 9p21.3; 17p13.2; 10q24.2; 14q21.3; 1p36.11 and 13q12.11, while significantly amplified were 3q28; 12q13.3 and 21q22.3. None of these aberrations were significant for low grade astrocytoma tumors, and we believe they might be associated with progression events.

Although we cannot be sure if our findings represent genetic “malignancy switch”, the majority of regions and genes within were previously reported for the process of progression towards malignancy.

Regions 17q25.3 and 8q24.3 that were found to be amplified on our total sample did not emerge in subsequent analyses and therefore may be characteristic for lower grades. Of note is that deletions 3p14.3, 11p15.4, 15q15.1, 16q22.1, 20q11.22 and 22q12.3 were all found in low grade samples at a threshold level of  $q$ -0.45 and also on our total sample at  $q$ -0.25, but were not repeatedly found in high grades. This may indicate that these regions and genes within may be involved as early events as well. Although many observed changes were similar to the literary reports, some were identified for the first time in our patients and associated with progression or as an early event.

We could not establish any differences between IDH1 mutant and WT tumors in regard to the presence of listed CNAs.

Even though drawing conclusions is complicated perhaps because of the inherent heterogeneity of astrocytomas [40] and complexity of cancer genomes per se, our bioinformatics results indicate compatibility with the previously reported regions. At first, cancer-related aCGH studies have showed a high level of discordance in the reported genomic aberrations [41], leading to conclusions that random mutations and CNA are prevalent. However, a newly developed tool GISTIC can distinguish which CNA are more functionally relevant to the cancer evolution. The accordance rate among different studies improved and a concordant picture of biologically significant CNAs in the glioma genome emerged [15].

Genes known to be the most frequently amplified in glioblastoma, *EGFR*, *CDK4*, *PDGFRA*, *MDM2*, *MDM4* [8,19] are all found to be involved in tumorigenesis of a variety of cancers and are members of several signaling pathways notoriously involved in cancer. Although these genes are highly involved in glioblastoma evolution, they cannot be considered as solely astrocytoma-specific since they are malfunctioning in a great number of different cancers. *EGFR* (7p11.2) is one of the most renowned members of the protein kinase superfamily and a member of Ras-Raf-MEK-ERK pathway, but can also activate PI3 kinase-AKT-mTOR signaling. The gene is amplified in 40% of glioblastomas and was associated with the so-called classical subtype. Nevertheless, *EGFR* amplification and mutations have been shown to be responsible for many other cancer types.

Another common amplification is of the chromosome 12 on which genes *CDK4* and *MDM2* reside. *CDK4* (cyclin dependent kinase 4), yet another candidate gene for glioblastoma, is responsible for the cell cycle's G1 to S transition but is also involved in a variety of cancers. *MDM2* is an E3 ubiquitin ligase localized in the nucleus that mediates ubiquitination of p53, leading to its degradation by the proteasome and inhibits p53- and p73-mediated cell cycle arrest and apoptosis. Similar involvement in glioblastoma displays gene *MDM4* [42].

The region 10q23.31 where tumor suppressor *PTEN* resides is also known to be frequently lost in glioblastoma, but also mutated or lost in a large number of other human tumors (prostate cancer, glioblastoma, endometrial, lung and breast cancer). The gene encodes a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase that contains a tensin like domain. It negatively regulates the AKT/PKB signaling pathway. We have observed significantly deleted region 10q24.2 distant 5814367bp from the *PTEN* region.

Another well-known amplification event is the one on chromosome 4 [8] where a gene for receptor tyrosine-protein kinase *PDGFRA* (4q12) resides. *PDGFRA* acts as a receptor for PDGFA, PDGFB and PDGFC growth factors necessary among other things for the growth of glial cells, too [43]. It has been shown that kinase *PDGFRA* mediates the activation of both PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling.

Of note is our result on the deletions of loci at 9p21.3, where genes *CDKN2A/CDKN2B* reside, that have been identified with GISTIC as significantly deleted regions both on our total sample as well as on malignant cases only. It has been shown that the region is significant for glioblastomas and highly recurrent homozygous deletions of *CDKN2A/B* genes were established [8]. *CDKN2A* functions as inhibitors of CDK4 kinase, which denotes this gene as a tumor suppressor. Its protein can also stabilize the p53 protein. Adjacent to *CDKN2A* lays *CDKN2B* gene which encodes a cyclin-dependent kinase inhibitor that disables the activation of CDK4 or CDK6. Both genes are involved in the G1 cell-cycle control.

Beroukhi et al. [15] report on amplifications of 4q12 and 7p11.2 (18–26% of samples) and deletions of 1p36.31 and 9p21.3 (35–49%). Their paper argues that, in some cases, a high degree of amplification renders amplifications highly significant even though they occur in only 6–7% of samples. Because the background rate of deletions across the genome is higher, deletions usually must occur at higher frequencies than amplifications to attain similar levels of significance.

Roerig et al. [13] found novel sites of losses such as 15q14–q26 in anaplastic astrocytomas, supporting our GISTIC results where region 15q15.1 was significantly deleted (even at 0.15 cutoff value). Another reported region 18q11.2–qter for secondary glioblastomas was significantly amplified in our group of pooled malignant cases (18q12.2;  $q=0.25$ ), but was missing from glioblastomas.

Several significant aberrant regions and genes within were further investigated using functional enrichment strategies [44]. According to DAVID, 65 genes were assigned to a pathway or a significantly over-represented functional category. Our results on annotated genes possibly involved in astrocytoma tumors brought many candidates which we allocated to the regions identified by GISTIC. In such a manner, potentially important genes in high grade samples were: *SOS2*, *FCN3*, *ZNF683*, *FGF9*, *IL17D*, *TNFRSF19*, *FLT3*, *POLR1D*, *FLT1*, *HMGB1*, genes for several interferon molecules, *C1QBP*, *CXCL16*, *DHX33*, *GP1BA*, *NLRP1*, *P2RX1*, *P2RX5*, *CLDN7*, *CLEC10A*, *GABARAP*, *XAF1*, *DVL2*, *RTN4RL1*, *YWHAE*, *BLNK*, *CHUK*, *ENTPD1*, *FGF8*, *HPS6*, *NFKB2*, *PIK3AP1*, *TAF5*, *TRIM8*, *WNT8B*. Only one significantly amplified region in high grades harbored functionally relevant annotated gene—*CLDN1*.

A significantly deleted region suspected as an early event harbored just one functionally annotated gene—*MAP1LC3A* (*LC3*).

Heat maps revealed a clear distinction between low and high grade samples showing that high grades were reflecting the general heat map images of the entire batch. Furthermore, in the majority of malignant samples, systematic amplification of segments in chromosome 7 and respective deletion in chromosome 10 were evident, a pattern previously reported for glioblastoma patients [26].

Next, we restricted our analysis to KEGG database and evidenced that only genes associated with deleted segments were significantly enriched in 18 out of 325 total *Homo sapiens* associated KEGG pathways. The most significantly represented pathways were PI3K-Akt, Cytokine-cytokine receptor interaction, NOD-like receptor, Jak-STAT, RIG-I-like receptor and Toll-like receptor. In addition, pathways involved in viral infections and inflammation were all significantly enriched too. The enrichment map revealed roughly equal systematic involvement of all genes across the identified pathways. Probably the most intriguing of those are enrichments within HPV and Herpes

simplex infection pathways as several studies indicated that the infectious agents have previously been associated with the carcinogenesis of brain and head and neck cancers [45–49]. There is evidence for a viral etiology for glioblastoma. It has been shown that many viruses can drive glioma formation in vitro and in xenograft models [50]. The most evident association is with the human Cytomegalovirus. Nevertheless, Hashida et al. [47] demonstrated the presence of the HPV viral genome and protein as well in a subset of patients with glioblastoma. However, the majority of literary findings are still contradictory.

The involvement of cytokine and pathways connected to inflammation that emerged as significantly represented in our study is not unusual. It has long been known that numerous cytokines are strongly implicated in the development and progression of cancer [51,52], but the mechanisms behind their complex involvement are not completely elucidated. Tumor cells communicate with various types of cells in the tumor microenvironment and this interaction can both promote and inhibit cancer progression depending on the context. Besides being involved in inflammation, cytokines and their receptors also mediating the host response to cancer, the relationship between cancer and inflammation is an important novel topic that needs to be explored further.

Interferons are small signaling proteins released by host cells with the aim to eradicate pathogens or tumors. Interferon gene cluster region on 9p21.3 has long been shown to be deleted in glioblastoma [53,54]. The same region was deleted in our study and 16 interferon genes (INF) emerged as significantly annotated by DAVID. This is in accordance with the study by Olopade et al. [55], who showed that loss of DNA sequences on 9p, particularly the IFN genes, occurred at a significant frequency in gliomas, and is important for the progression of these tumors. The cBioPortal for Cancer Genomics website (<http://www.cbioportal.org/>, accessed on 23 February 2019) data mining validated this finding since all of the genes within 9p21.3 region were also reported to be substantially deleted in high grade gliomas. Our results on many significantly implicated interferon genes are consistent with a model of tumorigenesis in which the development or progression of cancer involves the loss or inactivation of genes that normally act to fight tumorigenesis. This may suggest involvement of immunological impairment in gliomas.

It is relevant to discuss potential pharmaceuticals employed against the signaling pathways and genes described above. Recent therapeutic approaches target many levels of glioblastoma biology. One approach is the inhibition of cell cycle molecules. A great number of compounds have been tested as cyclin-dependent kinase (CDK) inhibitors in many malignancies including glioblastoma, yet the majority of them are in pre-clinical or phase I/II trials. Another strategy is immunotherapy that is also being tested in glioblastoma in pre-clinical or phase I/II trials. Furthermore, oligodeoxynucleotides that act on Toll signaling by binding to intracellular Toll-like receptor 9 (TLR9) and thus activate innate and adaptive immunity at first showed no improvement of overall survival of glioblastoma patients, but are being further investigated. Another interesting therapeutic target, and in line with our findings, is the targeting of EGFR. For example, the use of Rindopepimut1—the EGFRvIII mutation vaccine—shows great promise. EGFRvIII is a glioblastoma-specific EGFR mutation consisting of a deletion that causes constitutive activity of tyrosine kinase contributing to glioblastoma aggressiveness. It is important to mention that STAT signaling emerged as another potential therapeutic target in glioblastoma, since siRNAs or pharmacological inhibitors of STAT 3 and its activator, IL-6, showed promising results for several other malignancies including multiple myeloma, head and neck cancer and prostate cancer. Employing miRNAs and siRNA are trialed for suppression of Akt signaling, too [56]. Attempts to target the PI3K-Akt-mTOR pathway with PI3K, AKT, or mTORC1 inhibitors failed to improve survival, but switching to the inhibition of another player of this pathway, mTORC2, shows promise [57]. However, effective crossing of drugs and cells through the blood–brain barrier still represents a big problem; therefore, nanobodies and micelles are being investigated to bypass this obstacle.

The major limitation of our study is the small number of patients in our cohort. Nevertheless, the minute CNA investigation brings important findings. We are also aware that the roles of involved genes

within lost or gained regions need to be further explored by measuring their differential expression, but we must leave these experiments for future studies.

## 4. Materials and Methods

### 4.1. Astrocytoma Samples

The collected brain tumors were newly diagnosed and patients did not receive any treatment prior to surgical resection. The tumor samples were collected from the Departments of Neurosurgery University Hospital Centers Zagreb and “Sisters of Charity”, Zagreb, Croatia. The patients had no family history of brain tumors. The majority of collected glioblastomas were primary without IDH1 mutations; however, two cases were positive on IDH1 mutations and characterized as secondary. During the operative procedure, the tumors were removed using a microneurosurgical technique after which the tissue was frozen in liquid nitrogen and transported to the laboratory, where it was immediately transferred to  $-80^{\circ}\text{C}$ . The blood samples were collected in ethylenediaminetetraacetic acid (EDTA) and processed immediately. Eleven patients were male, and three were female. Patient age ranged from 19 to 72 years (mean: 49.29 years; median: 50.0 years). The data on astrocytoma molecular diagnosis is shown in Table 1. Diagnosis was established on the basis of the pathohistological findings by a board certified neuropathologist and classified according to WHO guidelines [9]. Magnetic resonance imaging (MRI) revealed the localization of astrocytic brain tumors. Ethical approvals were received from the Ethical Committees School of Medicine University of Zagreb (number: 380-59-10106-14-55/147, class: 641-01/14-02/01, 1 July 2014); and University Hospital Centers Zagreb (number: 02/21/JG, class: 8.1.-14/54-2, 23 June 2014.) and “Sisters of Charity” (number: EP-7426/14-9, 11 June 2014.), and the patients gave their informed consent.

### 4.2. DNA Extraction

Approximately 0.5 g of tumor tissue was homogenized with 1 mL extraction buffer (10 mM Tris HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) and incubated with proteinase K (100  $\mu\text{g}/\text{mL}$ ; Sigma-Aldrich, St. Louis, MO, USA; overnight at  $37^{\circ}\text{C}$ ). Phenol-chloroform extraction and ethanol precipitation followed. Blood was used to extract leukocyte DNA. Five ml of blood was lysed with 15 mL of RCLB (red blood cells lysis buffer; 155 mM  $\text{NH}_4\text{Cl}$ ; 0.1 mM EDTA; 12 mM  $\text{NaHCO}_3$ ) and centrifuged (15 min/ $5000\times g$ ) at  $4^{\circ}\text{C}$ . The pellet was further processed same as for DNA extraction from the tissue samples. Samples were purified using PCR purification kit (Qiagen, Hilden, Germany). The concentrations were measured by Nanodrop and the purity of DNA was determined. Each DNA sample was analyzed on 1.5% agarose gel to assess genomic DNA intactness and the average molecular weight.

### 4.3. aCGH

Array Comparative Genomic Hybridization (aCGH) was performed using SurePrint G3 Human CGH microarrays  $4 \times 180\text{ K}$  (Agilent Technologies, Santa Clara, CA, USA) following the manufacturer’s instructions. Briefly, 1  $\mu\text{g}$  of genomic DNAs corresponding to either a human reference control (Promega, Madison, WI, USA) or test samples were fragmented by heating at  $95^{\circ}\text{C}$  for 10 min. Fragmented DNAs were labeled with Cy3 (reference DNA) and Cy5 (test samples) fluorescent dUTP, respectively, using the SureTag Complete Labeling Kit (Agilent Technologies). Purification columns (Agilent) were used to remove the unincorporated nucleotides and dyes. The labeled samples along with human Cot-1 DNA were added together and hybridized on the array slides. Hybridizations of labeled DNAs to SurePrint G3 Human CGH Arrays ( $4 \times 180\text{ K}$ ) (Agilent Technologies) were performed in a hybridization oven at  $65^{\circ}\text{C}$  at 20 rpm for 24 h. The slide was scanned at 3  $\mu\text{m}$  resolution on Agilent Microarray Scanner System (G2565BA, Agilent Technologies). Agilent CytoGenomics software (version 4.0.2.21, Agilent Technologies) was used to visualize, detect, and analyze chromosomal patterns within the microarray profiles. The true copy number variation (CNV) in the test sample was

inferred from the log ratio of a minimum of 3 consecutive probes and gene content in the observed region. Recommended values of Agilent Technologies for log ratios in actual data are between +0.53 and −0.9.

#### 4.4. Bioinformatics Analysis

The pipeline utilized two main computational approaches in processing the data, namely rCGH (Bioconductor package, version 3.6, Memorial Sloan-Kettering Cancer Center, New York, NY, USA and University of California—San Francisco, San Francisco, CA, USA) and GISTIC (version 2.0.23, The Broad Institute of MIT and Harvard, Cambridge, MA, USA).

#### 4.5. Computation Analysis of CNAs

The R package rCGH [58] version 1.12.0 was used for pre-processing, genotyping and calculation of circular binary segmentation to estimate the normalized copy number values, with circular binary segmentation carried out as implemented in the DNACopy package [59] version 1.52.0, letting the standard deviation for segment length be defined from the data rather than setting it to some pre-specified value. The relative log ratio centering was executed by utilizing an expectation maximization algorithm, thus increasing the expectation level at which a signal is being detected to its maximum. Furthermore, to increase the efficacy of the estimation process, the pipeline models the LRR distribution based on segmentation, with each segment mean and SD value (derived from probes assigned to each given segment) utilized in the process. The value was set to 0.5. Germline copy number alterations were removed from the all downstream analysis by excluding sex chromosomes.

#### 4.6. Functional Enrichment Analysis

GISTIC is software designed for discovering new cancer genes targeted by somatic copy number alterations (SCNAs) [15,58]. Identifying whether significantly amplified or deleted regions within a chromosome GISTIC 2.0.23 was conducted by setting the confidence level to 99% for a range of  $q$ -value thresholds spanning from 0.05 to 0.45 with the increment of 0.1. Focal amplification or deletion for all hg19 samples was determined by setting the broad length cutoff to 0.5, and confidence level to 0.9, with all other parameters restricted to their default values.

In order to understand the biological relevance of a list of genes obtained by GISTIC, subsequent analysis was conducted using DAVID (version 6.8, National Cancer Institute at Frederick, Frederick, MD, USA) [60], a functional enrichment analysis tool designed to estimate the biological relevance of a given collection of genes was performed [61]. The clustering algorithm in DAVID is based on the hypothesis that similar annotations should have similar gene members. It uses the Kappa statistic to measure the degree of common genes between two annotations. This is followed by heuristic clustering to group similar annotations according to Kappa values. Relevant genes were evaluated against the background consisting of only those genes queried by the microarray. For Functional Annotation Clustering considering clusters with the enrichment scores higher than 1, a Fisher exact test was used to determine the significance of the obtained results utilizing two types of corrections for multiple hypothesis testing—Bonferroni [62] and Benjamini–Hochberg (BH) [63] adjusted  $p$ -values with a threshold level set to  $\alpha = 0.05$ .

Pathway enrichment analysis was performed with R packages cluster Profiler version 3.4.4 [59] and ReactomePA [64] using a KEGG [61] pathway database to further investigate the role of the GISTIC identified genes (associated to amplification and deletions sites) in known biological pathways considering only Benjamini–Hochberg adjusted  $p$ -values below 0.05 as significant. A list of the obtained KEGG pathways together with the associated genes were mapped using an R path view package [65]. Bar charts were used to illustrate the number of genes that overlap in both KEGG pathways and functional annotation clusters. Moreover, dot matrices were computed to reflect the impact of genes associated with each KEGG pathway as well as enrichment maps and GSEA plots [66].



## 5. Conclusions

As technologies progress, genetic profiles and molecular findings have become recognized as potential markers of clinical distinction of tumor subtypes. Molecular characteristics are also being helpful in explaining the responses to therapy. Identifying narrow regions with altered DNA copy number is an important finding in tumor genetics, as genes mapped in these regions may represent potential candidate tumor suppressor genes and oncogenes. Our findings demonstrate that CNA among benign pilocytic astrocytomas shared different patterns than observed in the malignant group. Numerous recurrent changes found in malignant high grades indicated the augmentation of aberrations as the disease progresses. The regions identified as significantly deleted and amplified in high grades, 9p21.3; 17p13.2; 10q24.2; 14q21.3; 1p36.11, 13q12.11, 3q28; 12q13.3 and 21q22.3 might be associated with progression events, while significant deletions at 3p14.3; 11p15.4; 15q15.1; 16q22.1; 20q11.22 and 22q12.3 were comprised of low grades to early stages of tumorigenesis. Implicated pathways were PI3K-Akt, Cytokine-cytokine receptor, NOD-like receptor, Jak-STAT, RIG-I-like receptor and Toll-like receptor pathways. HPV and herpes simplex infection pathways that were also presented proved the viral etiology for glioblastoma, while results on inflammatory pathways may suggest that immunological impairment is responsible too.

Despite many recent advances on the molecular biology of astrocytoma, its molecular blueprint of development and progression is still largely unexplained. Our data contributes to better understanding of human astrocytoma genetic profiles and suggests that copy number alterations play important roles in its etiology and progression. Hopefully the results of our analysis will find applicability in clinical oncology. It would be important to validate the involvement of candidate genes employing other methods of molecular biology in further studies.

**Supplementary Materials:** Supplementary materials can be found at <http://www.mdpi.com/1422-0067/20/5/1251/s1>. Figure S1. Enrichment map illustrates connectivity of significantly enriched pathways indicating the identified genes associated with deletion segments to be equally (more/less) represented in each identified pathway, Figure S2. Matrix layout for all genes within 18 KEGG pathways sorted by size. Dark circles in the matrix indicate functional categories with genes that are part of the intersection, that is, are associated with each pathway of the set. The bar plot above the matrix depicts the number of shared genes, while the bar plot on the left shows the number of genes within a given pathway. Blue colored histograms indicate that all genes are associated with deleted cytobands. Figure S3. Summary of the most important identified KEGG pathways with the genes associated with deleted chromosomal regions labeled in red. Table S1. List of genes within CNAs associated with significantly enriched functional categories as calculated using DAVID. Only significant functional enrichments are included with a significance level set to Bonferroni,  $p < 0.05$ . Furthermore, corresponding correction  $p$ -values were rounded up to three decimal points.

**Author Contributions:** N.P.-Š. produced the idea, designed the study, contributed to the data collection, analysis and interpretation of the results, wrote the manuscript and revised it for important intellectual content, and approved the final version of the manuscript. A.K. contributed to data acquisition and analysis, performed experimental work, read the manuscript and revised it for important intellectual content. K.G.J. performed experimental work, participated in data collection, interpretation and analysis, and revision of the manuscript for important intellectual content. M.L. participated in data analysis and interpretation and revised the manuscript for important intellectual content; A.B. contributed to the data interpretation, manuscript editing, and revised the manuscript for important intellectual content. R.B. performed biostatistical analysis and interpretation. F.B. contributed to data acquisition, the interpretation of the results, manuscript editing, and manuscript review. All authors read and approved the final manuscript.

**Funding:** This work was supported by grants from Croatian Science Foundation 6625 and 9386 and the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project “Experimental and clinical research of hypoxic-ischemic damage in perinatal and adult brain”; GA KK01.1.1.01.0007 funded by the European Union through the European Regional Development Fund).

**Conflicts of Interest:** The authors declare that they have no competing interests. The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## References

- Appin, C.L.; Brat, D.J. Molecular genetics of gliomas. *Cancer J.* **2014**, *20*, 66–72. [[CrossRef](#)]
- Abou-El-Ardat, K.; Seifert, M.; Becker, K.; Eisenreich, S.; Lehmann, M.; Hackmann, K.; Rump, A.; Meijer, G.; Carvalho, B.; Temme, A.; et al. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. *Neuro-Oncology* **2017**, *19*, 546–557. [[CrossRef](#)]
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **2008**, *455*, 1061–1068. [[CrossRef](#)] [[PubMed](#)]
- Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* **2010**, *17*, 98–110. [[CrossRef](#)]
- Chin, L.; Hahn, W.C.; Getz, G.; Meyerson, M. Making sense of cancer genomic data. *Genes Dev.* **2011**, *25*, 534–555. [[CrossRef](#)] [[PubMed](#)]
- Pećina-Šlaus, N.; Kafka, A.; Tomas, M.; Marković, L.; Okštajner, P.K.; Sukser, V.; Krušlin, B. Wnt signaling transcription factors TCF-1 and LEF-1 are upregulated in malignant astrocytic brain tumors. *Histol Histopathol.* **2014**, *29*, 1557–1564. [[CrossRef](#)]
- Kafka, A.; Tomas, D.; Lechpammer, M.; Gabud, T.; Pažanin, L.; Pećina-Šlaus, N. Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. *Dis. Markers* **2017**, *2017*, 9253495. [[CrossRef](#)]
- Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Nounshmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. *Cell* **2013**, *155*, 462–477. [[CrossRef](#)] [[PubMed](#)]
- Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol.* **2016**, *131*, 803–820. [[CrossRef](#)] [[PubMed](#)]
- Nasser, M.M.; Mehdipour, P. Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors. *Cell. Mol. Neurobiol.* **2017**, *38*, 393–419. [[CrossRef](#)]
- Paw, I.; Carpenter, R.C.; Watabe, K.; Debinski, W.; Lo, H.W. Mechanisms regulating glioma invasion. *Cancer Lett.* **2015**, *362*, 1–7. [[CrossRef](#)] [[PubMed](#)]
- Barbashina, V.; Salazar, P.; Holland, E.C.; Rosenblum, M.K.; Ladanyi, M. Allelic Losses at 1p36 and 19q13 in Gliomas: Correlation with Histologic Classification, Definition of a 150-kb Minimal Deleted Region on 1p36, and Evaluation of CAMTA1 as a Candidate Tumor Suppressor Gene. *Clin. Cancer Res.* **2005**, *11*, 1119–1128. [[PubMed](#)]
- Roerig, P.; Nessling, M.; Radlwimmer, B.; Joos, S.; Wrobel, G.; Schwaenen, C.; Reifenberger, G.; Lichter, P. Molecular classification of human gliomas using matrix-based comparative genomic hybridization. *Int. J. Cancer* **2005**, *117*, 95–103. [[CrossRef](#)] [[PubMed](#)]
- Ruano, Y.; Mollejo, M.; de Lope, A.R.; Hernández-Moneo, J.L.; Martínez, P.; Meléndez, B. Microarray-based comparative genomic hybridization (array-CGH) as a useful tool for identifying genes involved in Glioblastoma (GB). *Methods Mol. Biol.* **2010**, *653*, 35–45. [[CrossRef](#)] [[PubMed](#)]
- Beroukhi, R.; Getza, G.; Nghiemphue, L.; Barretina, J.; Hsuehe, T.; Linhart, D.; Vivanco, I.; Lee, J.C.; Huang, J.H.; Alexander, S.; et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 20007–20012. [[CrossRef](#)] [[PubMed](#)]
- Yang, T.H.; Kon, M.; Hung, J.H.; Delisi, C. Combinations of newly confirmed Glioma-Associated loci link regions on chromosomes 1 and 9 to increased disease risk. *BMC Med. Genom.* **2011**, *4*, 63. [[CrossRef](#)] [[PubMed](#)]
- Crespo, I.; Tao, H.; Nieto, A.B.; Rebelo, O.; Domingues, P.; Vital, A.L.; Patino Mdel, C.; Barbosa, M.; Lopes, M.C.; Oliveira, C.R.; et al. Amplified and Homozygously Deleted Genes in Glioblastoma: Impact on Gene Expression Levels. *PLoS ONE* **2012**, *7*, e46088. [[CrossRef](#)]
- Carter, N.P. Methods and strategies for analyzing copy number variation using DNA microarrays. *Nat. Genet.* **2007**, *39*, S16–S21. [[CrossRef](#)] [[PubMed](#)]
- Mohapatra, G.; Sharma, J.; Yip, S. Array CGH in Brain Tumors. *Methods Mol. Biol.* **2013**, *973*, 325–338. [[CrossRef](#)] [[PubMed](#)]

20. Banerjee, D. Array comparative genomic hybridization: An overview of protocols, applications, and technology trends. *Methods Mol. Biol.* **2013**, *973*, 1–13. [[CrossRef](#)] [[PubMed](#)]
21. Riegel, M. Human molecular cytogenetics: From cells to nucleotides. *Genet. Mol. Biol.* **2014**, *37*, 194–209. [[CrossRef](#)]
22. Ichimura, K.; Vogazianou, A.P.; Liu, L.; Pearson, D.M.; Bäcklund, L.M.; Plant, K.; Baird, K.; Langford, C.F.; Gregory, S.G.; Collins, V.P. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. *Oncogene* **2008**, *27*, 2097–2108. [[CrossRef](#)]
23. Yin, D.; Ogawa, S.; Kawamata, N.; Tunici, P.; Finocchiaro, G.; Eoli, M.; Ruckert, C.; Huynh, T.; Liu, G.; Kato, M.; et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. *Mol. Cancer Res.* **2009**, *7*, 665–677. [[CrossRef](#)]
24. Hesson, L.B.; Cooper, W.N.; Latif, F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. *Oncogene* **2007**, *26*, 7283–7301. [[CrossRef](#)]
25. Brunner, C.; Jung, V.; Henn, W.; Zang, K.D.; Urbschat, S. Comparative genomic hybridization reveals recurrent enhancements on chromosome 20 and in one case combined amplification sites on 15q24q26 and 20p11p12 in glioblastomas. *Cancer Genet. Cytogenet.* **2000**, *121*, 124–127. [[CrossRef](#)]
26. Mermel, C.H.; Schumacher, S.E.; Hill, B.; Meyerson, M.L.; Beroukhi, R.; Getz, G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol.* **2011**, *12*, R41. [[CrossRef](#)]
27. Beroukhi, R.; Mermel, C.H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J.S.; Dobson, J.; Urashima, M.; et al. The landscape of somatic copy-number alteration across human cancers. *Nature* **2010**, *463*, 899–905. [[CrossRef](#)]
28. Marko, N.F.; Weil, R.J. The molecular biology of WHO grade I astrocytomas. *Neuro-Oncology* **2012**, *14*, 1424–1431. [[CrossRef](#)] [[PubMed](#)]
29. Jones, D.T.; Hutter, B.; Jäger, N.; Korshunov, A.; Kool, M.; Warnatz, H.J.; Zichner, T.; Lambert, S.R.; Ryzhova, M.; Quang, D.A.; et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nat. Genet.* **2013**, *45*, 927–932. [[CrossRef](#)]
30. Pečina-Šlaus, N.; Gotovac, K.; Kafka, A.; Tomas, D.; Borovečki, F. Genetic changes observed in a case of adult pilocytic astrocytoma revealed by array CGH analysis. *Mol. Cytogenet.* **2014**, *7*, 95. [[CrossRef](#)] [[PubMed](#)]
31. Jones, D.T.; Kocialkowski, S.; Liu, L.; Pearson, D.M.; Ichimura, K.; Collins, V.P. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. *Oncogene* **2009**, *28*, 2119–2123. [[CrossRef](#)] [[PubMed](#)]
32. Ward, S.J.; Karakoula, K.; Phipps, K.P.; Harkness, W.; Hayward, R.; Thompson, D.; Jacques, T.S.; Harding, B.; Darling, J.L.; Thomas, D.G.; et al. Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation. *J. Neurooncol.* **2010**, *98*, 305–318. [[CrossRef](#)] [[PubMed](#)]
33. Seifert, M.; Garbe, M.; Friedrich, B.; Mittelbronn, M.; Klink, B. Comparative transcriptomics reveals similarities and differences between astrocytoma grades. *BMC Cancer* **2015**, *15*, 952. [[CrossRef](#)] [[PubMed](#)]
34. Fleischer, M.; Kessler, R.; Klammer, A.; Warnke, J.P.; Eschrich, K. LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas. *Genes Chromosomes Cancer* **2011**, *50*, 1010–1020. [[CrossRef](#)] [[PubMed](#)]
35. Bidinotto, L.T.; Torrieri, R.; Mackay, A.; Almeida, G.C.; Viana-Pereira, M.; Cruvinel-Carlioni, A.; Spina, M.L.; Campanella, N.C.; Pereira de Menezes, W.; Clara, C.A.; et al. Copy Number Profiling of Brazilian Astrocytomas. *G3 (Bethesda)* **2016**, *6*, 1867–1878. [[CrossRef](#)] [[PubMed](#)]
36. Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A., Jr.; Kinzler, K.W. Cancer Genome Landscapes. *Science* **2013**, *339*, 1546–1558. [[CrossRef](#)] [[PubMed](#)]
37. Bass, A.J.; Watanabe, H.; Mermel, C.H.; Yu, S.; Perner, S.; Verhaak, R.G.; Kim, S.Y.; Wardwell, L.; Tamayo, P.; Gat-Viks, I.; et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat. Genet.* **2009**, *41*, 1238–1242. [[CrossRef](#)] [[PubMed](#)]
38. Firestein, R.; Bass, A.J.; Kim, S.Y.; Dunn, I.F.; Silver, S.J.; Guney, I.; Freed, E.; Ligon, A.H.; Vena, N.; Ogino, S.; et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. *Nature* **2008**, *455*, 547–551. [[CrossRef](#)] [[PubMed](#)]
39. Lin, W.M.; Baker, A.C.; Beroukhi, R.; Winckler, W.; Feng, W.; Marmion, J.M.; Laine, E.; Greulich, H.; Tseng, H.; Gates, C.; et al. Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res.* **2008**, *68*, 664–673. [[CrossRef](#)] [[PubMed](#)]



40. Sottoriva, A.; Spiteri, I.; Piccirillo, S.G.; Touloumis, A.; Collins, V.P.; Marioni, J.C.; Curtis, C.; Watts, C.; Tavaré, S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 4009–4014. [[CrossRef](#)] [[PubMed](#)]
41. Ali, H.; Bitar, M.S.; Al Madhoun, A.; Marafie, M.; Al-Mulla, F. Functionally-focused algorithmic analysis of high resolution microarray-CGH genomic landscapes demonstrates comparable genomic copy number aberrations in MSI and MSS sporadic colorectal cancer. *PLoS ONE* **2017**, *12*, e0171690. [[CrossRef](#)] [[PubMed](#)]
42. Crespo, I.; Vital, A.L.; Gonzalez-Tablas, M.; Patino Mdel, C.; Otero, A.; Lopes, M.C.; de Oliveira, C.; Domingues, P.; Orfao, A.; Tabernero, M.D. Molecular and Genomic Alterations in Glioblastoma Multiforme. *Am. J. Pathol.* **2015**, *185*, 1820–1833. [[CrossRef](#)] [[PubMed](#)]
43. Roskoski, R., Jr. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. *Pharmacol. Res.* **2018**, *129*, 65–83. [[CrossRef](#)] [[PubMed](#)]
44. Harris, M.A.; Clark, J.; Ireland, A.; Lomax, J.; Ashburner, M.; Foulger, R.; Eilbeck, K.; Lewis, S.; Marshall, B.; Mungall, C.; et al. The Gene Ontology (GO) database and informatics resource. *Nucleic Acids Res.* **2004**, *32*, D258–D261. [[CrossRef](#)] [[PubMed](#)]
45. Wrensch, M.; Weinberg, A.; Wiencke, J.; Miike, R.; Sison, J.; Wiemels, J.; Barger, G.; DeLorenze, G.; Aldape, K.; Kelsey, K. History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls. *Am. J. Epidemiol.* **2005**, *161*, 929–938. [[CrossRef](#)] [[PubMed](#)]
46. Alibek, K.; Kakpenova, A.; Baiken, Y. Role of infectious agents in the carcinogenesis of brain and head and neck cancers. *Infect. Agent Cancer* **2013**, *8*, 7. [[CrossRef](#)] [[PubMed](#)]
47. Hashida, Y.; Taniguchi, A.; Yawata, T.; Hosokawa, S.; Murakami, M.; Hiroi, M.; Ueba, T.; Daibata, M. Prevalence of human cytomegalovirus, polyomaviruses, and oncogenic viruses in glioblastoma among Japanese subjects. *Infect. Agent Cancer* **2015**, *10*, 3. [[CrossRef](#)] [[PubMed](#)]
48. Strong, M.J.; Blanchard, E., 4th; Lin, Z.; Morris, C.A.; Baddoo, M.; Taylor, C.M.; Ware, M.L.; Flemington, E.K. A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association. *Acta Neuropathol. Commun.* **2016**, *4*, 71. [[CrossRef](#)] [[PubMed](#)]
49. Zavala-Vega, S.; Castro-Escarpulli, G.; Hernández-Santos, H.; Salinas-Lara, C.; Palma, I.; Mejía-Aranguré, J.M.; Gelista-Herrera, N.; Rembao-Bojorquez, D.; Ochoa, S.A.; Cruz-Córdova, A.; et al. An overview of the infection of CMV, HSV 1/2 and EBV in Mexican patients with glioblastoma multiforme. *Pathol. Res. Pract.* **2017**, *213*, 271–276. [[CrossRef](#)] [[PubMed](#)]
50. McFaline-Figueroa, J.R.; Wen, P.Y. The Viral Connection to Glioblastoma. *Curr. Infect. Dis. Rep.* **2017**, *19*, 5. [[CrossRef](#)] [[PubMed](#)]
51. Lacalle, R.A.; Blanco, R.; Carmona-Rodríguez, L.; Martín-Leal, A.; Mira, E.; Mañes, S. Chemokine Receptor Signaling and the Hallmarks of Cancer. *Int. Rev. Cell Mol. Biol.* **2017**, *331*, 181–244. [[CrossRef](#)] [[PubMed](#)]
52. Silginer, M.; Nagy, S.; Happold, C.; Schneider, H.; Weller, M.; Roth, P. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. *Neuro-Oncology* **2017**, *19*, 1338–1349. [[CrossRef](#)] [[PubMed](#)]
53. Fountain, J.W.; Karayiorgou, M.; Taruscio, D.; Graw, S.L.; Buckler, A.J.; Ward, D.C.; Dracopoli, N.C.; Housman, D.E. Genetic and physical map of the interferon region on chromosome 9p. *Genomics* **1992**, *14*, 105–112. [[CrossRef](#)]
54. Tarasova, I.A.; Tereshkova, A.V.; Lobas, A.A.; Solovyeva, E.M.; Sidorenko, A.S.; Gorshkov, V.; Kjeldsen, F.; Bubis, J.A.; Ivanov, M.V.; Ilina, I.Y.; et al. Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. *Oncotarget* **2018**, *9*, 1785–1802. [[CrossRef](#)] [[PubMed](#)]
55. Olopade, O.I.; Jenkins, R.B.; Ransom, D.T.; Malik, K.; Pomykala, H.; Nobori, T.; Cowan, J.M.; Rowley, J.D.; Diaz, M.O. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. *Cancer Res.* **1992**, *52*, 2523–2529. [[PubMed](#)]
56. Geraldo, L.H.M.; Garcia, C.; da Fonseca, A.C.C.; Dubois, L.G.F.; de Sampaio E Spohr, T.C.L.; Matias, D.; de Camargo Magalhães, E.S.; do Amaral, R.F.; da Rosa, B.G.; Grimaldi, I.; et al. Glioblastoma Therapy in the Age of Molecular Medicine. *Trends Cancer* **2019**, *5*, 46–65. [[CrossRef](#)]
57. Mecca, C.; Giambanco, I.; Donato, R.; Arcuri, C. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence. *Dis. Markers* **2018**, *2018*, 9230479. [[CrossRef](#)]

58. Commo, F.; Guinney, J.; Ferté, C.; Bot, B.; Lefebvre, C.; Soria, J.C.; André, F. rCGH: A comprehensive array-based genomic profile platform for precision medicine. *Bioinformatics* **2016**, *32*, 1402–1404. [[CrossRef](#)]
59. Seshan, V.E.; Olshen, A. Dnacopy: DNA Copy Number Data Analysis; Available online: <https://bioc.ism.ac.jp/packages/3.6/bioc/html/DNACopy.html> (accessed on 13 November 2018).
60. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **2009**, *4*, 44–57. [[CrossRef](#)]
61. Kanehisa, M.; Furumichi, M.; Tanabe, M.; Sato, Y.; Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* **2017**, *45*, D353–D361. [[CrossRef](#)]
62. Bland, J.M.; Altman, D.G. Multiple significance tests: The Bonferroni method. *BMJ* **1995**, *310*, 170. [[CrossRef](#)] [[PubMed](#)]
63. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J. R. Statist. Soc. B* **1995**, *57*, 289–300. [[CrossRef](#)]
64. Yu, G.; He, Q.Y. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. *Mol. Biosyst.* **2016**, *12*, 477–479. [[CrossRef](#)] [[PubMed](#)]
65. Luo, W.; Brouwer, C. Pathview: An R/Bioconductor package for pathway-based data integration and visualization. *Bioinformatics* **2013**, *29*, 1830–1831. [[CrossRef](#)]
66. Morgan, M.; Falcon, S.; Gentleman, R. Gseabase: Gene Set Enrichment Data Structures and Methods. Available online: <https://rdrr.io/bioc/GSEABase/> (accessed on 13 November 2018).



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).